Novartis' Afinitor Goes To Panel Review With Trouble Areas For FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The Oncology Drugs Advisory Committee will review everolimus for certain advanced neuroendocrine tumors on April 12; the pivotal trial used progression-free survival and a crossover design, both areas that FDA has critiqued.